Skip to main content
Top
Published in: Journal of Inflammation 1/2013

Open Access 01-08-2013 | Poster presentation

Lipopolysaccharide (LPS) segmental lung challenge in nonhuman primates – a model of airway inflammation

Authors: Franklin J Schlerman, Andrea G Bree, Michael D Wadanoli, Samuel J Goldman, Cara MM Williams, Joseph P Sypek

Published in: Journal of Inflammation | Special Issue 1/2013

Login to get access

Excerpt

We developed a reproducible model of neutrophilic inflammation in cynomolgus monkeys (Macaca fascicularis) in order to study potential novel anti-inflammatory compounds intended for respiratory diseases such as COPD and asthma. Using a pediatric bronchoscope, a baseline bronchoalveolar lavage (BAL) was performed on the left lung prior to LPS segmental challenge to the right lung. At 24, 72 and 168 hours post challenge, BAL fluid (BALF) was collected to assess the level of pulmonary inflammation. At both 24 and 72 hours (Hr) post LPS challenge, total BAL cells were significantly elevated over baseline. BAL cell differentials revealed that mean percent neutrophils significantly increased from baseline (1.3±1.6%) to (74.0 ± 21.9% at 24 Hr and 26.6 ± 21.0% at 72 Hr) whereas, BAL macrophage numbers had significantly decreased from baseline (94.4 ± 3.1%) to (31.6 ± 21.2 % at 24 Hr and 64.2 ± 20.1% at 72 Hr) post challenge. In addition to increased inflammation, we also observed a significant increase in BAL cell gene expression of MMP-9 and significant increases in sCD14 and IL-8 from concentrated BALF 24 Hr post challenge. Numbers of infiltrating cells and other inflammatory parameters returned to baseline levels by 168 Hr following LPS challenge. In some studies, intramuscular injections of dexamethasone (Dex [1 mg/kg]) were administered 24 Hr prior and just prior to LPS challenge. Dex did not significantly reduce total BAL inflammation or IL-8 protein, but did significantly reduce percent neutrophils and sCD14 protein within the BALF 24 hours post challenge. Dex also significantly increased percent macrophages 24 Hr post challenge. These data show that segmental challenge with LPS produces an acute pulmonary neutrophilic inflammation, which is reduced by pretreatment with Dex. This reproducible, short-term, large animal model may help us to better understand neutrophillic inflammation pathways contributing to lung injury and host defense. …
Metadata
Title
Lipopolysaccharide (LPS) segmental lung challenge in nonhuman primates – a model of airway inflammation
Authors
Franklin J Schlerman
Andrea G Bree
Michael D Wadanoli
Samuel J Goldman
Cara MM Williams
Joseph P Sypek
Publication date
01-08-2013
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue Special Issue 1/2013
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-10-S1-P29

Other articles of this Special Issue 1/2013

Journal of Inflammation 1/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.